- LOGIN
- MemberShip
- 2026-04-10 17:07:08
- Policy
- PVA, the higher the bill, the greater the discount rate
- by Lee, Tak-Sun Mar 08, 2023 05:52am
- Lee Sang-il, executive director of NHIS, held a meeting with the Korea Special Press Association on the 7thThe NHIS plans to increase the reduction rate of the upper limit for drugs with high claims in the PVA, and lower the reduction rate or exclude drugs with low claims. This is based on research conducted last year. The results of the research service (performance evaluation and improvement plan of PVA (researcher: Bae Seung-jin, Ewha Womans University)) has not yet been disclosed, but will be disclosed at the end of this month and discussed at the Workie Group, which will be held from May. At the Korea Special Press Association meeting held on the 7th with Lee Sang-il, executive director of the NHIS, this PVA improvement plan was revealed for the first time. Director Lee said, "In order to improve the effectiveness of drug cost management, we conducted a research service last year to evaluate the performance of the PVA system and improve it." As a way to improve the system, we suggested selective management of drugs with high fiscal impact and efficient system operation.” Accordingly, a plan was devised to expand the selection criteria for usage type 'Ka' by adding 5 billion won and 10% increase conditions from the existing 30% increase condition for the selective management of drugs with high financial impact. The reference formula is differentiated by dividing it into three sections according to the size of the bill, and a plan to increase the maximum reduction rate in consideration of the coefficient of the reference formula was proposed. As a result, the plan is to increase financial efficiency by increasing the reduction rate for drugs with high claims. Currently, the maximum reduction rate is limited to 10%, but the maximum reduction rate is expected to exceed 10% for drugs with high claims through improvement measures. Conversely, a plan was proposed to further include drugs with low claims, which have a small reduction rate and are excluded from negotiations. For efficient operation of the system, the exclusion criteria will be raised from 2 billion to 3 to 5 billion, and a temporary refund system will be introduced. In addition, a plan to lower the maximum reduction rate for small-amount drugs was also proposed. The temporary refund system refers to a one-time refund to the NHIS by a pharmaceutical company for a price cut instead of a price cut for a drug whose usage has temporarily increased due to a pandemic or other reasons. The target and materialization plan will be discussed in the working group to be held in May, but this plan is not expected to be promoted immediately as a mid-term task. Jeong Hae-min, head of the NHIS Pharmaceutical Management Office, said, “The rest of the parts except for the temporary refund system are short-term tasks, and we plan to promote system improvement through a working group that will be held from May.” We plan to operate according to the schedule of, and based on the matters discussed through this, we will come up with an improvement plan, revise the relevant regulations in the second half of the year, and implement them from next year.” A plan to correct the number of drugs related to COVID-19 has also been outlined to some extent. The target drugs are cold medicines and antibiotics that are encouraged to be produced by the Ministry of Food and Drug Safety, and it is explained that they correspond to about 2,600 items based on the 2022 benefit list. As for the correction method, a method of correcting the usage amount was proposed, excluding the period (month) when usage increased sharply during the pandemic, and the director Lee explained that they are currently in final coordination with the pharmaceutical industry. The NHIS plans to finalize the correction plan this month when discussions with the pharmaceutical industry are completed and to apply to monitor for negotiations in April.
- Company
- Celltrion Healthcare published clinical result of Remsima SC
- by Hwang, Jin-joon Mar 08, 2023 05:51am
- An official from Celltrion Healthcare is giving a presentation on Remsima SC at ECCO. (Photo by Celltrion Healthcare)Celltrion Healthcare announced on the 6th in Copenhagen, Denmark, that it was holding the '2023 European Crohn's Disease and Colitis Society (ECCO)' for four days from the 1st (local time), and 'Remsima SC' was held for the purpose of US approval. announced that it had unveiled a new global clinical trial of '. The first clinical trial is the result of analyzing the efficacy and safety of Remsima SC compared to placebo during maintenance therapy after administering Remsima to patients with Crohn's disease (CD). It was released as a digital oral presentation online. 343 patients with moderate to severe CD were randomly assigned to the Remsima SC treatment group and the placebo control group in a 2:1 ratio at week 10 and compared at week 54. Clinical outcome The primary endpoint, clinical remission (CR), was 62.3% for Remsima SC and 32.1% for placebo. In the endoscopic response (ER), Remsima SC 51.1% and placebo 17.9%, a statistically higher efficacy result than the control group was confirmed. No new safety issues were identified with Remsima SC maintenance treatment. The second clinical trial was released through a poster presentation as a result of analyzing whether Remsima SC maintained a statistically significant advantage over placebo in phase 3 clinical trials for patients with ulcerative colitis (UC). After 438 patients with UC were treated with Remsima up to week 10, they were randomly assigned to receive Remsima SC or placebo in a 2:1 ratio, and data from week 54 were compared. The CR set as the primary evaluation index for clinical results was 43.2% in the Remsima SC-administered group, higher than 20.8% in the placebo control group. No new safety issues were found in the clinical trial. The results of the post-clinical phase 1 post-analysis confirming the correlation between high serum trough concentration and low immunogenicity of Remsima SC were also released as a poster. Predictors of Immunogenicity in IBD Patients Treated with Infliximab: According to CT-P13 SC Phase 1 Post-Clinical Analysis', maintenance treatment with Remsima SC confirmed that the proportion of patients whose blood concentration reached a certain threshold or higher was higher than that of patients receiving an intravenous injection. done. Through this, indices such as antibody to the drug (ADA) and neutralizing antibody (NAb) involved in the immune process were lower, confirming the potential advantage of Remsima SC in terms of immunogenicity. Celltrion Healthcare also published three posters, including 'Network meta-analysis for comparative evaluation of the efficacy of Infliximab IV and SC and Vedolizumab IV and SC in the maintenance treatment of patients with Crohn's disease and ulcerative colitis'. presented at the conference.
- Policy
- Free vaccination of Rotarix·RotaTeq is available
- by Lee, Jeong-Hwan Mar 07, 2023 05:39am
- The Korea Centers for Disease Control and Prevention (KCDC) will start a national vaccination project for Rotavirus vaccines Rotarix and RotaTeq, which are distributed in Korea, from the 6th. From this day, infants aged 2 to 6 months who are subject to vaccination will be able to receive one of the two vaccines free of charge at nationally consigned medical institutions or public health centers. Rotavirus is easily spread through the hands and mouths of infants from contaminants in diapers or toys. Infection can cause vomiting, high fever, and severe diarrhea, leading to dehydration and requiring hospitalization. Even if the 1st rotavirus vaccine was charged for 6 days before the implementation date of the national vaccination program, free vaccination is possible from the remaining 2nd or 3rd vaccination for complete vaccination. Rota vaccination requires 2 or 3 doses depending on the type of vaccine used to obtain the sufficient preventive effect. Rotarix requires a total of 2 doses and RotaTeq requires a total of 3 doses. The current status of the nearest vaccination institution can be checked on the vaccination helper website. Rotarix and RotaTeq are classified into monovalent and pentavalent depending on the number of serotypes included in the vaccine, but both vaccines showed similar efficacy and safety in terms of preventing rotavirus infection and severe disease in Korea. Since cross-inoculation is not allowed, it should be noted that after the first vaccination, all rounds must be completed only with the same manufacturer's vaccine. Director Ji Young-mi of the Agency for Disease Control and Prevention said, “The introduction of this national rotavirus vaccination will lower the cost burden for parents who needed about 200,000 to 300,000 won for vaccination,” and “the incidence of rotavirus infection, which causes acute diarrhea and high fever in infants, will also decrease. I expect that," he said.
- Policy
- ‘Improve rare disease designations standards for equity'
- by Lee, Jeong-Hwan Mar 07, 2023 05:38am
- The claim that Korea’s rare disease designation standards should be improved and expanded to ease the disease burden borne by patients from drug costs, etc. The request arose with the rising need to address the irrationalities in the current rare disease designation system, such as those from the unclear diagnostic criteria set due to the extremely small number of patients or irrational standards set for acquired (secondary) rather than congenital diseases. On the 6th, Professor Hyun-Young Kim of Pediatric Surgery at Seoul National University Hospital claimed so during her presentation at the ‘Discussions for a national measure to manage life-threatening rare diseases’ that was held at the Members' Office Building of the National Assembly. The meeting was hosted by Rep. Sun-Woo Kang of the Democratic Party of Korea. Professor Kim's presentation was about ‘Limitations in the designation of rare diseases and application of special calculations.’ The Rare Disease Management Act defines a rare disease as a ‘disease that affects fewer than 20,000 people, or whose number of carriers is unknown because diagnosis of the disease is difficult, which is determined according to the procedures and standards prescribed by Ordinance of the Ministry of Health and Welfare.’ Most treatments for diseases that are designated as rare diseases can be applied the special calculation system, which allows the patient’s coinsurance rate to be reduced to 10% of all medical expenses. Due to this, the burden of treatment and drug expense among rare disease patients whose condition has not been designated as a rare disease increases significantly and is excluded from legal support Regarding the limitations in rare disease designations, Kim pointed out that there is a gap between the definition and designation of a rare disease, and the problem of equity in designation and non-designation exists even in the same disease depending on whether the condition is congenital or acquired. Also, she raised the issue of how patients with secondary conditions that suffer the same symptoms, disease burden, and pain as the congenital condition are not allowed designation as a rare disease. Professor Kim said, “It is necessary to designate rare diseases after comprehensive consideration of the characteristic of the disease, the pain suffered by the patients, and its effect on the quality of life. The authorities should provide ample opportunity for relevant academic societies and patient groups to submit opinions and actively review the designations.” As an example, Professor Kim pointed to short bowel syndrome to point out the issues that exist in Korea’s rare disease designation system. Short bowel syndrome is not designated as a rare disease as it affects over 20,000 patients and is an infectious and transient condition with a low socioeconomic cost. Also, the fact that it is a secondary disease and has unclear diagnostic criteria and diagnosis was also a reason for its non-designation as a rare disease. In other words, patients with congenital short bowel syndrome can receive special calculation benefits for their treatment expense with a rare disease designation, but patients with acquired short bowel syndrome are deprived of the same benefit. This non-designation of rare diseases has led to the non-application of reimbursement for a short bowel syndrome treatment. In Korea, teduglutide was approved to treat short bowel syndrome in 2018. However, the drug is unavailable for use due to its non-reimbursement. Without reimbursement, the drug costs KRW 50 million with 3-6 month administration, and KRW 100 million with 1-year administration. Professor Kim stressed, “In Korea, if the doctors work hard and save the patients, the patients cannot receive the benefit as they exceed the rare diseases designations standards. The standards need to be improved to provide benefit to these rare disease patients who are left unattended in the blind spot."
- Company
- Exkivity applies for reimbursement
- by Eo, Yun-Ho Mar 07, 2023 05:38am
- Exkivity, an anti-cancer drug targeting EGFR exon 20 insertion mutation, is aiming for insurance coverage. Takeda Korea recently submitted a reimbursement application for Exkivity, a treatment for non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation. This drug targets the same biomarker as Janssen's Rybrevant but differs in that it is an oral drug. EGFR Exon 20 insertion mutation is a new biomarker that has recently attracted attention in the field of non-small cell lung cancer. Currently available anticancer drugs are suitable for Exon19 deletion or Exon21 L858R substitution mutation, which are commonly found in EGFR mutations, but EGFR Exon20 was still a blind spot. Accordingly, it remains to be seen whether GFR exon 20 insertion mutation non-small cell lung cancer targeting anticancer drugs can be listed in Korea. In the case of Rybrevant, it failed to cross the HIRA barrier after applying for benefits once. Rybrevant proved its efficacy through a phase 1/2 study conducted on 114 patients with non-small cell lung cancer with an EGFR exon 20 insertion mutation who had previously received platinum-based chemotherapy. Clinical results, in the patient group who took Rybrevant 160 mg, the ORR evaluated by IRC was 28% and the mDOR was 17.5 months. In particular, the median reaction time after administration of Rybrevant was 1.9 months, confirming that the drug's effect appears quickly from the beginning of treatment. mPFS was 7.3 months and mOS was 24.0 months. The safety profile was also found to be favorable. The most common adverse reactions were diarrhea, rash, and fatigue, which can be managed by adjusting the dose.
- Policy
- ‘RSA may be applied to non-rare innovative new drugs'
- by Lee, Jeong-Hwan Mar 07, 2023 05:38am
- Chang-Hyun Oh, Director of Pharmaceutical Benefits at the Ministry of Health and Welfare The Ministry of Health and Welfare announced it will improve its policy to allow innovative new drugs to be listed for reimbursement through the risk-sharing assessment (RSA) track even if they are not anticancer or rare disease treatments if they demonstrate a clinical effect. If allowed, it is expected that the scope of drugs that are applied RSA will increase, and more drugs that are not designated as rare disease may be promptly listed for reimbursement as long as they have a good effect. Chang-Hyun Oh, Director of Pharmaceutical Benefits at the Ministry of Health and Welfare, said so at the ‘Discussions for the national measure to manage life-threatening rare diseases’ that was held at the National Assembly on the 6th. Director Oh said, “Only anticancer drugs and rare disease drugs are currently applied RSA, however, we plan to pave the way to take the innovativeness of drugs into account and apply RSA to those drugs. We are discussing how to apply RSA to drugs that clinically demonstrate an improvement in quality of life by determining the scope of recognizing innovation for drugs.” Director Oh reiterated the need to set an appropriate drug price compensation policy for innovative new drugs that the ministry had announced as an improvement task this year. Although the ministry had been flexible in applying the reimbursement listing system to life-threatening diseases until now, Director Oh said that the ministry will introduce a system that can improve patient access to drugs that were not designated as rare disease drugs in the future. Director Oh said, “We will discuss measures to allow the application of RSA to treatments that are not designated as rare diseases to allow compensation of their appropriate drug price as long as the treatments have verified their efficacy. For example, diseases such as generalized pustular psoriasis and short bowel syndrome have not been designated as rare diseases, but we will set a standard that can recognize the innovativeness of these treatments as well.” He added, “Although pharmaceutical companies would need to share a part of the burden, we will contemplate ways to open up opportunities for new reimbursement listings this year. We haven’t decided on to what extent we will be recognizing the innovativeness, but will make more efforts under the policy goal of expanding access to new drugs.”
- Company
- Boryung officially launches Zepzelca
- by Kim, Jin-Gu Mar 06, 2023 05:56am
- Boryung announced on the 28th that it has officially launched Zepzelca, a new small-cell lung cancer drug, in Korea. Zepzelca is a new anticancer drug developed by PharmaMar S.A. It is used for metastatic small-cell lung cancer that has failed first-line platinum-based chemotherapy. Zepzelca is a new drug with a mechanism that simultaneously shows 'apoptosis of cancer cells through inhibition of DNA transcription' and inhibition of cancer cell proliferation, immune checkpoint action, and angiogenesis through suppression of transcriptional activity in Tumor-Associated Macrophage (TAM). Zepzelca was approved by the Ministry of Food and Drug Safety in September of last year and will be distributed to medical institutions in earnest through this official launch. It was released in July 2020 in the US. Zepzelca has established itself as a representative second-line treatment for small-cell lung cancer in the United States, with sales of $535 million until last year. Currently, more than 40% of patients with small cell lung cancer are prescribed Zepzelca as a second-line treatment. In Korea, Boryung has held exclusive sales and distribution rights for Zepzelca since 2017. Boryung expects the use of Zepzelca to expand as there are not many types of second-line or higher small-cell lung cancer treatments in Korea. According to the literature supporting the approval of Zepzelca published in The Lancet Oncology, an overall response of 35% based on the entire patient group, the average duration of response of 5.3 months, ease of administration given once every 3 weeks, and manageable side effects such as clinical benefits such as existing drug The contrast effect is evaluated as excellent. For this reason, Zepzelca is also recommended in the NCCN and ESMO guidelines. Young-seok Kim, head of Boryung Onco Division, said, "So far, the options for second-line treatment have been limited for patients with small cell lung cancer who have failed platinum-based chemotherapy."
- Policy
- Tecentriq fails urothelial carcinoma trial but beneficial
- by Lee, Hye-Kyung Mar 06, 2023 05:56am
- Although the conditional clinical trial failed for Roche’s cancer immunotherapy ‘Tecentriq,’ experts in Korea decided to recognize Tecentriq’s benefit for ‘patients with locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy’ and maintain the indication as it is unethical to reorder clinical trials when these patients have no other alternatives. According to the minutes of the Central Pharmaceutical Affairs Council meeting that was held on November 28th last year which was recently disclosed by the Ministry of Food and Drug Safety, the CPAC members decided to recognize the benefit of the therapeutic confirmatory clinical trial results on Tecentriq. At the time, Roche’s subsidiary Genentech had voluntarily withdrawn Tecentriq’s indication in the US for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. In the US, Roche had first acquired Tecentriq’s bladder cancer indication through the Accelerated Approval Program under the condition of conducting a confirmatory trial, then conducted a Phase III IMvigor130 trial to evaluate Tecentriq plus platinum-based chemotherapy for the first-line treatment of people with previously untreated advanced bladder cancer. However, as the designated postmarketing requirement (PMR) did not meet the primary endpoint of overall survival (OS) for Tecentriq plus chemotherapy compared with chemotherapy alone, the company had withdrawn the indication. In 2017, Tecentriq was conditionally approved for the ‘treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 tumor proportion score of at least 5%,’ under the condition that it conducts a therapeutic confirmatory trial to demonstrate superiority over chemotherapy in urothelial carcinoma. The MFDS asked the CPAC to “determine whether the indication should be maintained despite the recent results in the current situation where treatment options have not changed much for urothelial carcinoma since 2017.” To the request, one CPAC member said, “Tecentiq showed an improvement over chemotherapy in some of the efficacy endpoints such as DOR in ITT or PD-L1 positive patients. Therefore, we need to maintain the approval status to offer options to such patients.” The member's opinion was that not many options exist for patients who cannot use platinum-based chemotherapy and that it is better to maintain approval, even if it is a conditional one if the results show a similar level of effect to chemotherapy. Another member said, “Based on the trial, Tecentriq’s combined use with chemotherapy should be excluded, and the indication for patients who are not eligible for platinum-based chemotherapy should be maintained as they have no other options. Therefore, what we need to decide is whether to maintain the indication for patients that can use carboplatin.” The committee chair added the opinion that the company should reconduct the clinical trial in principle. The CPAC chair said, “In principle, the company should conduct the trial again. What matters most is the therapeutic efficacy, so we need to decide whether it is appropriate to allow Tecentriq’s use in all situations and options.” Also, an opinion that it would be better to maintain the indication for patients without options was raised, pointing to how it would not be appropriate to create a situation where the committee's conclusion deprives patients of the only option they may have. The chair concluded, “Although Tecentriq failed the confirmatory trial in urothelial carcinoma, we conclude that we acknowledge the benefits of the drug as it is unethical to order the company to reconduct a clinical trial when patients with locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy have no other alternatives.” Meanwhile, Roche Korea is known to be discussing whether to maintain Tecentriq’s urothelial carcinoma indication in Korea, with regards to the voluntary withdrawal of the urothelial carcinoma indication in the US.
- Company
- ‘No regrets...happy to have served at Daiichi Sankyo Korea'
- by Eo, Yun-Ho Mar 06, 2023 05:56am
- Dae Jung Kim, President of Daiichi Sankyo Korea “I have no regrets. Although I have no specific plans set for the future, I would like to say it was a great honor to have served over 30 years at Daiichi Sankyo, and will cherish the memory forever.” Dae Jung Kim (63), President of Daiichi Sankyo Korea and the longest-serving multinational pharmaceutical company CEO in Korea, is leaving the industry. Although the company headquarters proposed to extend his term, President Kim has respectfully expressed his intention to resign. As successor, Daiichi Sankyo Korea recently appointed Jeong-tae Kim (49), the current vice president of Daiichi Sankyo Korea, as the new president. Accordingly, President Dae Jung Kim will retire at the end of this month (March) and remain as an advisor to help the company for the time being. “After dividing the employees into over 20 teams, I have been holding farewell parties with them for almost 2 months. Having served such a long time, I wanted to personally meet each and every one of my employees and express my gratitude. I will be leaving the beloved company after completing the overseas workshop that we haven’t been able to conduct due to COVID-19.” After being appointed as President of Daiichi Sankyo Korea in 2010, President Kim led the Korean subsidiary for 15 years. Also, President Kim had been working at Daiichi Pharmaceutical before the company merged with Sankyo in 2007. Kim joined Daiichi Pharmaceutical in 1991. After leaving the company to acquire an MBA, he returned to work in the US office and Japanese headquarters and led the M&A process of the Korean subsidiary. Although Daiichi was not his first place of work, Kim had been with Daiichi Sankyo for nearly 30 years. Kim said, “During my term, I worked to stay true to principle. I believe the role of multinational pharmaceutical companies in Korea is pretty clear. Rather than conduct research or manufacture products, the companies need to supply the products that they have already developed to the Korean patients. Based on this belief, I worked to deliver accurate instructions on how to use the product we introduced to Korea. We thoroughly monitored variables that could occur on-site, unlike in the clinical setting, and focused on improving the knowledge of our employees to ensure accurate information delivery.” While reminiscing, Kim chose the patent term expiry of ‘Olmetec’ as his most difficult period. “At the time, sales of Olmetec fell by nearly 20% due to the inflow of its generics and the price cut that followed. So we decided to take on a ‘choose and focus’ strategy and set the slogan ‘to become reborn as a cardiology treatment specialist,' based on which we discontinued the domestic promotional activity for our antibacterial agent ‘Cravit.' Fortunately, the strategy showed an effect. This decision was solely made by the Korean subsidiary, and we were the only one in the Asia-Pacific region to make such a decision.’ “As a result, we accumulated knowledge and rapport in cardiology, which led to the success of the fourth new oral anticoagulant (NOAC), ‘Lixiana.’ Of course, factors such as the performance of our partners also contributed to the success, so it was a result of everyone's efforts." Immediately after his retirement, President Kim plans to trek the 750km Haeparang trail alone for 50 days. Kim made time for such solitary walks at every turning point of his life. “I only have gratitude and thanks to express to my executives and employees at Daiichi Sankyo Korea. As a leader, I have long been in a position where I had to set a direction and lead the people forward. Having experienced the joys and sorrows together, I want to express thanks to the many that believed in me and followed me through difficult times. I owe my safe retirement to my executives and employees."
- Opinion
- [Reporter's view]Is the Drug Price Reduction Act Good?
- by Kim, Jin-Gu Mar 06, 2023 05:56am
- The fate of the so-called drug price reduction/refund law will be decided sooner or later. It is expected that a decision will be made within this month at the earliest, whether it will be possible to limit the tricks of avoiding drug price cuts for original drugs for several years by applying for suspension of execution. The amendment to the National Health Insurance Act, which passed the Health and Welfare Committee of the National Assembly, was initially put on hold by the Legislation and Judiciary Committee and was likely to fail. However, it was revived as the Health and Welfare Committee decided to directly refer to the plenary session centering on the opposition party. As a result, this amendment is awaiting the final decision of the plenary session of the National Assembly. The plenary session was scheduled for the 23rd and 30th of this month. In the past, there has been a fierce debate over this amendment. The Ministry of Health and Welfare and the opposition party, which favored the bill, put forward the pharmacist's trick and the leakage of health insurance finances as justification. Opposing legal circles and judiciary committees fought back with the logic that the right to request a trial, a legitimate remedy for rights guaranteed by the Constitution, was violated. In the current situation where the opposition party is the majority, the amendment bill seems to be weighted toward passage. For a resolution at the plenary session, the presence of a majority of the current members and the consent of a majority of the members present is required. In other words, the possibility of passing the plenary session, tied to other agenda items, has increased. If the amendment is finally passed, pharmaceutical companies will have to vomit the health insurance finances invested during the drug price cut suspension period if they lose the prominent lawsuit in the future. The problem is that in the process, there is a risk of shrinking the lawsuit claims of pharmaceutical companies. Of course, the abuse of the judicial system will disappear, but it is pointed out that even if the drug price cut is felt to be unfair, even the opportunity to legitimately dispute it can be limited. In terms of the judicial system, there are also criticisms that it can undermine the essence of the suspension system. The bigger problem is then. If the amendment is passed, there is a possibility that the second and third legislations that reduce the right to request a trial will follow. Legislation that limits the right to appeal for a plausible cause is only difficult for the first time and relatively easy for the second and third. The argument in favor of the amendment can be reinterpreted as not a problem if the drug companies' right to file a lawsuit is slightly reduced if it is to root out the abuse of the suspension system and thereby prevent health insurance financial leaks. No matter how repugnant a pharmaceutical company is, it cannot violate even the fundamental rights of the Constitution. It is time to think about whether the drug price reduction method is the only way to prevent pharmaceutical companies from cheating.
